Wedbush Raises Oruka Therapeutics Price Target to $85
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ORKA?
Wedbush raised the firm's price target on Oruka Therapeutics to $85 from $45 and keeps an Outperform rating on the shares. The firm reviewed anticipated benchmarks and stock setup for upcoming induction data from the Phase 2a EVERLAST-A trial of ORKA-001 for psoriasis. Wedbush speculates a data readout is likely in May, and models a valuation of $4.77B for ORKA-001 in a base case scenario with PASI-100 rates of 35%-40%, consistent with other IL-23 mAbs in psoriasis. Further, the firm anticipates tiered upside scenarios with PASI-100 efficacy thresholds of 40%-50%, 50%-60%, and over 60% yielding respective valuations of $5.56B, $6.35B, and $14.2B based on expected market share increases and progressively accelerated trial timelines. Oruka remains one of Wedbush's top picks for 2026 and the firm sees room for sustained growth even from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ORKA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ORKA
Wall Street analysts forecast ORKA stock price to fall
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 68.920
Low
40.00
Averages
51.67
High
75.00
Current: 68.920
Low
40.00
Averages
51.67
High
75.00
About ORKA
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wedbush Raises Oruka Therapeutics Price Target to $85
- Price Target Increase: Wedbush raised the price target for Oruka Therapeutics (ORKA) from $45 to $85 while maintaining an Outperform rating, reflecting strong confidence in the company's future performance.
- Clinical Trial Outlook: The firm anticipates preliminary data from the Phase 2a EVERLAST-A trial of ORKA-001 for psoriasis to be released in May, generating significant market anticipation that could drive stock price appreciation.
- Valuation Model: Wedbush models a valuation of $4.77 billion for ORKA-001 under base case assumptions of 35%-40% PASI-100 efficacy, aligning with the performance of other IL-23 mAbs, indicating substantial market potential.
- Growth Expectations: The firm forecasts tiered upside scenarios with PASI-100 efficacy thresholds of 40%-50%, 50%-60%, and over 60%, yielding respective valuations of $5.56 billion, $6.35 billion, and $14.2 billion, suggesting sustained growth opportunities for the company.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Analysis of Oruka Therapeutics Options Trading
- Options Selling Risks: Selling puts on Oruka Therapeutics does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, and unless the stock declines 39.5%, the only benefit is a 57.5% annualized return from the premium.
- Historical Volatility Analysis: The trailing twelve-month volatility for Oruka Therapeutics is calculated at 72%, which, when combined with fundamental analysis, can help investors assess whether selling puts at a $35 strike price is worthwhile, especially with the current stock price at $57.19.
- Market Trading Dynamics: As of Tuesday afternoon, the put volume among S&P 500 components reached 1.98 million contracts, while call volume was at 2.53 million, resulting in a put:call ratio of 0.78, indicating an unusually high number of put buyers compared to historical norms.
- Options Market Trends: The current put trading volume significantly exceeds the long-term median ratio of 0.65, suggesting that investors are increasingly cautious about Oruka Therapeutics' future performance, potentially signaling concerns about the stock's downside risks.
See More
ORUKA THERAPEUTICS: BARCLAYS INCREASES TARGET PRICE FROM $50 TO $78
Company Overview: OruKare Therapeutics is a company involved in the healthcare sector, focusing on innovative therapeutic solutions.
Stock Price Update: Barclays has raised the price target for OruKare Therapeutics' stock from $50 to $78, indicating a positive outlook for the company's future performance.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
Wedbush Raises Oruka Therapeutics Price Target to $85
- Price Target Increase: Wedbush raised the price target for Oruka Therapeutics (ORKA) from $45 to $85 while maintaining an Outperform rating, reflecting strong confidence in the company's future performance.
- Clinical Trial Outlook: The firm anticipates preliminary data from the Phase 2a EVERLAST-A trial of ORKA-001 for psoriasis to be released in May, generating significant market anticipation that could drive stock price appreciation.
- Valuation Model: Wedbush models a valuation of $4.77 billion for ORKA-001 under base case assumptions of 35%-40% PASI-100 efficacy, aligning with the performance of other IL-23 mAbs, indicating substantial market potential.
- Growth Expectations: The firm forecasts tiered upside scenarios with PASI-100 efficacy thresholds of 40%-50%, 50%-60%, and over 60%, yielding respective valuations of $5.56 billion, $6.35 billion, and $14.2 billion, suggesting sustained growth opportunities for the company.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
Analysis of Oruka Therapeutics Options Trading
- Options Selling Risks: Selling puts on Oruka Therapeutics does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, and unless the stock declines 39.5%, the only benefit is a 57.5% annualized return from the premium.
- Historical Volatility Analysis: The trailing twelve-month volatility for Oruka Therapeutics is calculated at 72%, which, when combined with fundamental analysis, can help investors assess whether selling puts at a $35 strike price is worthwhile, especially with the current stock price at $57.19.
- Market Trading Dynamics: As of Tuesday afternoon, the put volume among S&P 500 components reached 1.98 million contracts, while call volume was at 2.53 million, resulting in a put:call ratio of 0.78, indicating an unusually high number of put buyers compared to historical norms.
- Options Market Trends: The current put trading volume significantly exceeds the long-term median ratio of 0.65, suggesting that investors are increasingly cautious about Oruka Therapeutics' future performance, potentially signaling concerns about the stock's downside risks.
See More
ORUKA THERAPEUTICS: BARCLAYS INCREASES TARGET PRICE FROM $50 TO $78
Company Overview: OruKare Therapeutics is a company involved in the healthcare sector, focusing on innovative therapeutic solutions.
Stock Price Update: Barclays has raised the price target for OruKare Therapeutics' stock from $50 to $78, indicating a positive outlook for the company's future performance.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
